Post-Marketing Observational Study of Safety Following Vaccination With Flublok Compared to Licensed IIV in Adults 18 Years of Age and Older
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Protein Sciences Corporation
- 11 Oct 2017 Status changed from active, no longer recruiting to completed.
- 17 Jun 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
- 17 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.